{"nctId":"NCT01072448","briefTitle":"12-week Efficacy of Indacaterol","startDateStruct":{"date":"2010-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":323,"armGroups":[{"label":"Indacaterol 75 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 75 μg"]},{"label":"Placebo to indacaterol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol"]}],"interventions":[{"name":"Indacaterol 75 μg","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \\[GOLD\\] Guidelines, 2008) and:\n\n  * Smoking history of at least 10 pack-years\n  * Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value\n  * Post-bronchodilator FEV1/FVC (forced vital capacity) \\< 70%\n\nExclusion criteria:\n\n* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular co-morbid conditions Other protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of albuterol during screening, and FEV1 pre-dose and 50-70 minutes post-dose of ipratropium during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.013"},{"groupId":"OG001","value":"1.26","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Transition Dyspnea Index (TDI) Total Score at the End of the Study (Week 12, Day 84)","description":"An independent (where feasible), trained assessor interviewed the patient and rated the degree of impairment due to dyspnea on a scale from -3 (major deterioration) to 3 (major improvement) on 3 domains (functional impairment, magnitude of task, and magnitude of effort) in comparison with baseline. A total score of the 3 domains ranged from -9 to 9; minus scores indicate deterioration. The analysis included baseline dyspnea index, FEV1 pre-dose and 10-15 minutes post-dose of albuterol during screening, and FEV1 pre-dose and 50-70 minutes post-dose of ipratropium during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.284"},{"groupId":"OG001","value":"0.11","spread":"0.287"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":163},"commonTop":["Chronic obstructive pulmonary disease","Headache","Urinary tract infection"]}}}